{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-060444","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.783423+00:00","generated_at":"2026-06-02T01:43:10.426410+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Novavax and Sanofi enter $500M upfront collaboration; Sanofi buys $68.8M in stock","bullets":["$500M non-refundable upfront payment; up to $700M in milestones for COVID products.","Additional milestones up to $200M per Adjuvant Product (first four); royalties mid-single to low-twenties percent.","Sanofi acquires 6.88M shares at $10/share (~$68.8M) in private placement.","Sanofi gets co-exclusive rights to commercialize Novavax's COVID vaccines globally from 2025/2026 season."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-060444","json":"https://secwatch.observer/filing/0001104659-24-060444.json","markdown":"https://secwatch.observer/filing/0001104659-24-060444.md","text":"https://secwatch.observer/filing/0001104659-24-060444.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000110465924060444/0001104659-24-060444-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000110465924060444/tm2414089d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:43:10.426410+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3ec8b9667735587971f53857eabe5ad5abaf3a7f","claim":"NOVAVAX INC entered into Collaboration and License Agreement with Sanofi Pasteur Inc. valued at $500 million (effective 2024-05-10).","evidence_excerpt":"On May 10, 2024, Novavax, Inc. (the “Company”) entered into a collaboration and license agreement (the “Collaboration and License Agreement”) with Sanofi Pasteur Inc. (“Sanofi”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465924060444/0001104659-24-060444-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Sanofi Pasteur Inc."},{"label":"Value","value":"$500 million"},{"label":"Effective","value":"2024-05-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}